IMPORTANCE: The lack of prospective randomized clinical trials demonstrating that full-body skin examination (FBSE) reduces melanoma morbidity or mortality has prompted an "I" rating from the United States Preventive Services Task Force for population-based skin cancer screening. More data on these screening programs are needed. OBJECTIVES: To describe a skin cancer screening quality initiative in a large health care system and to determine if the intervention was associated with screening of a demographically higher-risk population than previous screening programs and if melanoma incidence and thickness differed in screened vs unscreened patients. DESIGN, SETTING, AND PARTICIPANTS: This observational evaluation of a prospectively implemented quality initiative was conducted in a large health care system in western Pennsylvania (University of Pittsburgh Medical Center, UPMC) among adults seen in an office visit by a UPMC-employed primary care physician (PCP) in 2014. INTERVENTIONS: Implementation of a campaign promoting annual skin cancer screening by FBSE, including training of PCPs, promotion of the initiative to physicians and patients, and modification of the electronic health record (EHR) to include FBSE as a recommended preventive service for patients 35 years or older. MAIN OUTCOMES AND MEASURES: Characteristics of screened and unscreened patients and melanomas detected among them. RESULTS: Of 333 735 adult patients seen in an office visit by PCPs in 2014, 53 196 patients (15.9% of the screen-eligible population) received an FBSE, and 280 539 did not. Screened patients were slightly older (median age, 60 vs 57 years; P < .001) but did not differ significantly by sex (43.2% vs 43.1% men; P = .49) from the unscreened population. Fifty melanomas were diagnosed in screened patients and 104 melanomas were diagnosed in unscreened patients. Screened patients were more likely than unscreened patients to be diagnosed with melanoma (adjusted risk ratio [RR], 2.4; 95% CI, 1.7-3.4; P < .001) and to have a thinner invasive melanoma (median thickness, 0.37 mm vs 0.65 mm; P < .001). The incidence of melanoma lesions 1 mm or thicker was similar in screened vs unscreened patients (adjusted RR, 0.7; 95% CI, 02.-2.2; P = .52). CONCLUSIONS AND RELEVANCE: Large-scale screening for melanoma within a United States health care system is feasible and can result in increased detection of thinner melanomas. This intervention also resulted in screening of a higher proportion of men and an older patient population than previous screening interventions in which younger individuals and women predominated.
IMPORTANCE: The lack of prospective randomized clinical trials demonstrating that full-body skin examination (FBSE) reduces melanoma morbidity or mortality has prompted an "I" rating from the United States Preventive Services Task Force for population-based skin cancer screening. More data on these screening programs are needed. OBJECTIVES: To describe a skin cancer screening quality initiative in a large health care system and to determine if the intervention was associated with screening of a demographically higher-risk population than previous screening programs and if melanoma incidence and thickness differed in screened vs unscreened patients. DESIGN, SETTING, AND PARTICIPANTS: This observational evaluation of a prospectively implemented quality initiative was conducted in a large health care system in western Pennsylvania (University of Pittsburgh Medical Center, UPMC) among adults seen in an office visit by a UPMC-employed primary care physician (PCP) in 2014. INTERVENTIONS: Implementation of a campaign promoting annual skin cancer screening by FBSE, including training of PCPs, promotion of the initiative to physicians and patients, and modification of the electronic health record (EHR) to include FBSE as a recommended preventive service for patients 35 years or older. MAIN OUTCOMES AND MEASURES: Characteristics of screened and unscreened patients and melanomas detected among them. RESULTS: Of 333 735 adult patients seen in an office visit by PCPs in 2014, 53 196 patients (15.9% of the screen-eligible population) received an FBSE, and 280 539 did not. Screened patients were slightly older (median age, 60 vs 57 years; P < .001) but did not differ significantly by sex (43.2% vs 43.1% men; P = .49) from the unscreened population. Fifty melanomas were diagnosed in screened patients and 104 melanomas were diagnosed in unscreened patients. Screened patients were more likely than unscreened patients to be diagnosed with melanoma (adjusted risk ratio [RR], 2.4; 95% CI, 1.7-3.4; P < .001) and to have a thinner invasive melanoma (median thickness, 0.37 mm vs 0.65 mm; P < .001). The incidence of melanoma lesions 1 mm or thicker was similar in screened vs unscreened patients (adjusted RR, 0.7; 95% CI, 02.-2.2; P = .52). CONCLUSIONS AND RELEVANCE: Large-scale screening for melanoma within a United States health care system is feasible and can result in increased detection of thinner melanomas. This intervention also resulted in screening of a higher proportion of men and an older patient population than previous screening interventions in which younger individuals and women predominated.
Authors: Martin A Weinstock; Laura K Ferris; Melissa I Saul; Alan C Geller; Patricia M Risica; Julia A Siegel; Francis X Solano; John M Kirkwood Journal: Cancer Date: 2016-07-08 Impact factor: 6.860
Authors: Melody J Eide; Maryam M Asgari; Suzanne W Fletcher; Alan C Geller; Allan C Halpern; Waqas R Shaikh; Lingling Li; Gwen L Alexander; Andrea Altschuler; Stephen W Dusza; Ashfaq A Marghoob; Elizabeth A Quigley; Martin A Weinstock Journal: J Am Board Fam Med Date: 2013 Nov-Dec Impact factor: 2.657
Authors: Markus P Anders; Sandra Nolte; Annika Waldmann; Marcus Capellaro; Beate Volkmer; Rüdiger Greinert; Eckhard W Breitbart Journal: Eur J Public Health Date: 2014-04-23 Impact factor: 3.367
Authors: Alan C Geller; Rüdiger Greinert; Craig Sinclair; Martin A Weinstock; Joanne Aitken; Mathieu Boniol; Marcus Capellaro; Jean-Francois Doré; Mark Elwood; Suzanne W Fletcher; Richard Gallagher; Sara Gandini; Allan C Halpern; Alexander Katalinic; Robin Lucas; Ashfag A Marghoob; Sandra Nolte; Joachim Schüz; Margaret A Tucker; Beate Volkmer; Eckhard Breitbart Journal: Cancer Epidemiol Date: 2010-04-08 Impact factor: 2.984
Authors: A Waldmann; S Nolte; M A Weinstock; E W Breitbart; N Eisemann; A C Geller; R Greinert; B Volkmer; A Katalinic Journal: Br J Cancer Date: 2012-01-31 Impact factor: 7.640
Authors: Kirsten Bibbins-Domingo; David C Grossman; Susan J Curry; Karina W Davidson; Mark Ebell; John W Epling; Francisco A R García; Matthew W Gillman; Alex R Kemper; Alex H Krist; Ann E Kurth; C Seth Landefeld; Carol M Mangione; William R Phillips; Maureen G Phipps; Michael P Pignone; Albert L Siu Journal: JAMA Date: 2016-07-26 Impact factor: 56.272
Authors: June K Robinson; Namita Jain; Ashfaq A Marghoob; William McGaghie; Michael MacLean; Pedram Gerami; Brittney Hultgren; Rob Turrisi; Kimberly Mallett; Gary J Martin Journal: J Gen Intern Med Date: 2018-02-05 Impact factor: 5.128
Authors: Margaret A Tucker; David E Elder; Michael Curry; Mary C Fraser; Virginia Pichler; Deborah Zametkin; Xiaohong R Yang; Alisa M Goldstein Journal: J Invest Dermatol Date: 2018-02-08 Impact factor: 8.551
Authors: Martha Matsumoto; Aaron Secrest; Alyce Anderson; Melissa I Saul; Jonhan Ho; John M Kirkwood; Laura K Ferris Journal: J Am Acad Dermatol Date: 2017-11-24 Impact factor: 11.527
Authors: Susan M Swetter; Julia Chang; Amanda R Shaub; Martin A Weinstock; Eleanor T Lewis; Steven M Asch Journal: JAMA Dermatol Date: 2017-08-01 Impact factor: 10.282
Authors: Alan C Geller; Judith K Ockene; Mukti Kulkarni; Linda C Churchill; Christine F Frisard; Catherine A Okuliar; Karen M Ashe; Sybil L Crawford; M Ann Shaw; Katherine M White; Lori A Pbert Journal: Am J Prev Med Date: 2018-11 Impact factor: 5.043
Authors: Megan H Trager; Dawn Queen; Faramarz H Samie; Richard D Carvajal; David R Bickers; Larisa J Geskin Journal: Am J Med Date: 2019-11-09 Impact factor: 4.965
Authors: Alisa M Goldstein; Margaret A Tucker; Michael R Sargen; Ruth M Pfeiffer; David E Elder; Xiaohong R Yang Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-04 Impact factor: 4.090
Authors: Michael B Atkins; Clara Curiel-Lewandrowski; David E Fisher; Susan M Swetter; Hensin Tsao; Julio A Aguirre-Ghiso; Maria S Soengas; Ashani T Weeraratna; Keith T Flaherty; Meenhard Herlyn; Jeffrey A Sosman; Hussein A Tawbi; Anna C Pavlick; Pamela B Cassidy; Sunandana Chandra; Paul B Chapman; Adil Daud; Zeynep Eroglu; Laura K Ferris; Bernard A Fox; Jeffrey E Gershenwald; Geoffrey T Gibney; Douglas Grossman; Brent A Hanks; Douglas Hanniford; Eva Hernando; Joanne M Jeter; Douglas B Johnson; Samir N Khleif; John M Kirkwood; Sancy A Leachman; Darren Mays; Kelly C Nelson; Vernon K Sondak; Ryan J Sullivan; Glenn Merlino Journal: Clin Cancer Res Date: 2021-01-07 Impact factor: 13.801